Dr. Su et al. correctly point out that arrhythmias associated with haloperidol occur primarily after parenteral administration of the drug in medically ill patients but rarely in healthy individuals receiving recommended oral doses. However, their comment that clinicians should comply "with the spirit of the ‘black box’ warning by the…FDA" for ziprasidone is incorrect. Neither the FDA nor any regulatory agency has given ziprasidone a black box warning; nor does any agency recommend ECG monitoring when this drug is prescribed for its indication. Atypical antipsychotics are superior to older treatments for schizophrenia (4). Unfortunately, all presently available atypical antipsychotics can cause medical problems (weight gain, increased lipid levels, diabetes, etc.). Ziprasidone treatment produces longer QTc intervals than risperidone, olanzapine, or quetiapine, and this is reason for concern. However, to date, we know of no evidence that prolongation of the QTc interval during ziprasidone therapy is associated with torsades de pointes, even though more than 150,000 patients have been exposed to long-term therapy with this drug (S.J. Romano, senior medical director, Pfizer, Inc., personal communication). To require a pretreatment ECG for healthy young or middle-aged patients creates an unnecessary obstacle to ziprasidone treatment and denies patients any potential advantage of ziprasidone.